Moody's: Gilead view to positive

Moody's Investors Service said it revised the outlook on Gilead Sciences, Inc. to positive from stable and affirmed its Baa1 senior unsecured ratings.

This action follows the FDA approval of Sovaldi, Gilead's innovative treatment for hepatitis C.

"The positive outlook reflects the potential for a significant improvement in Gilead's cash flow, financial flexibility, and business diversity if Sovaldi achieves strong sales results," Moody's senior vice president Michael Levesque said in a news release.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.